KRAS and breast carcinoma: For example, a recent report demonstrated that treatment of ER+ breast cancer and KRAS-mutant NSCLC cells with eIF4A inhibitor could inhibit cell cycle feedback response and drug-resistance to CDK4/6 inhibitor treatment24.